Sign In
Buy QTRX
Quanterix Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | -$0.310 |
| EPS actual | -$0.390 |
| EPS Surprise | -25.81% |
| Revenue estimate | 36.841M |
| Revenue actual | 36.415M |
| Revenue Surprise | -1.16% |
| Release date | Mar 02, 2026 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.380 |
| EPS Surprise | -40.74% |
| Revenue estimate | 38.214M |
| Revenue actual | 43.855M |
| Revenue Surprise | 14.76% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.360 |
| EPS Surprise | -56.52% |
| Revenue estimate | 37.952M |
| Revenue actual | 40.15M |
| Revenue Surprise | 5.79% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.410 |
| EPS actual | -$0.470 |
| EPS Surprise | -14.63% |
| Revenue estimate | 38.51M |
| Revenue actual | 24.454M |
| Revenue Surprise | -36.50% |
Last 4 Quarters for Quanterix
Below you can see how QTRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $5.51 |
| EPS estimate | -$0.410 |
| EPS actual | -$0.470 |
| EPS surprise | -14.63% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $5.86 |
| Aug 04, 2025 | $6.04 |
| Aug 05, 2025 | $5.96 |
| Aug 06, 2025 | $5.61 |
| Aug 07, 2025 | $5.51 |
| Aug 08, 2025 | $4.75 |
| Aug 11, 2025 | $4.58 |
| Aug 12, 2025 | $4.76 |
| Aug 13, 2025 | $4.79 |
| 4 days before | -5.97% |
| 4 days after | -13.07% |
| On release day | -13.79% |
| Change in period | -18.26% |
| Release date | Nov 10, 2025 |
| Price on release | $5.12 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.360 |
| EPS surprise | -56.52% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $5.21 |
| Nov 05, 2025 | $5.17 |
| Nov 06, 2025 | $4.99 |
| Nov 07, 2025 | $4.94 |
| Nov 10, 2025 | $5.12 |
| Nov 11, 2025 | $5.00 |
| Nov 12, 2025 | $5.22 |
| Nov 13, 2025 | $5.32 |
| Nov 14, 2025 | $5.74 |
| 4 days before | -1.73% |
| 4 days after | 12.11% |
| On release day | -2.34% |
| Change in period | 10.17% |
| Release date | Mar 02, 2026 |
| Price on release | $6.33 |
| EPS estimate | -$0.270 |
| EPS actual | -$0.380 |
| EPS surprise | -40.74% |
| Date | Price |
|---|---|
| Feb 24, 2026 | $5.70 |
| Feb 25, 2026 | $6.29 |
| Feb 26, 2026 | $6.72 |
| Feb 27, 2026 | $6.55 |
| Mar 02, 2026 | $6.33 |
| Mar 03, 2026 | $5.87 |
| Mar 04, 2026 | $5.86 |
| Mar 05, 2026 | $5.31 |
| Mar 06, 2026 | $5.06 |
| 4 days before | 11.05% |
| 4 days after | -20.06% |
| On release day | -7.27% |
| Change in period | -11.23% |
| Release date | May 06, 2026 |
| Price on release | $3.29 |
| EPS estimate | -$0.310 |
| EPS actual | -$0.390 |
| EPS surprise | -25.81% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $3.13 |
| May 01, 2026 | $3.40 |
| May 04, 2026 | $3.37 |
| May 05, 2026 | $3.30 |
| May 06, 2026 | $3.29 |
| May 07, 2026 | $2.75 |
| May 08, 2026 | $2.83 |
| May 11, 2026 | $2.80 |
| May 12, 2026 | $2.91 |
| 4 days before | 5.11% |
| 4 days after | -11.55% |
| On release day | -16.41% |
| Change in period | -7.03% |
Quanterix Earnings Call Transcript Summary of Q1 2026
Quanterix reported Q1 2026 revenue of $36.4M (+20% YoY headline, -21% organic) with consumables in line but instrumentation softer due to timing. Management (new CEO Everett Cunningham) emphasized strategic shifts after his first 100 days: refocusing from integration to growth, investing in commercial effectiveness (lead generation reps, market development leaders, Thermo Fisher distribution), prioritizing the Simoa HD‑X upgrade with an IVD submission targeted for 2027, and accelerating the LucentAD Complete Alzheimer's diagnostics path (hiring a seasoned diagnostics leader, investing in lab infrastructure, and partnering with Tempus AI). They reiterated commitment to hit cash‑flow breakeven in H2 2026 and end‑2026 cash around $100M with no debt. Financials: GAAP gross margin ~42.7% (non‑GAAP margin 50.9%), adjusted EBITDA loss of $9.8M, cash of $102.6M, quarterly cash usage $19M (adjusted $14.7M). The company has delivered the $85M annualized cost synergies from the Akoya acquisition and will stop reporting further synergy realization. Guidance for 2026 remains $169–$174M revenue, GAAP gross margin 41–45%, non‑GAAP gross margin 49–53%. Management expects Q2 roughly flat to slightly ahead of Q1 and stronger commercial execution and product launches to drive a second‑half revenue ramp.
